Floatz logo

Axitinib

Sarcomatoid Renal Cell Carcinoma

Hao ZengSmall moleculePhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

11 Active assets in the Sarcomatoid Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
City of Hope Medical Center
Phase 3BB
Sorafenib
National Cancer Institute (NCI)
Phase 2BB
Bms-907351
City of Hope Medical Center
Phase 3BB
Ipilimumab
City of Hope Medical Center
Phase 3BB
gw786034
Mayo Clinic
Phase 2B

View all 18 →

Same molecule, other indications

Axitinib is also rated in:

kidney neoplasmDormant
BB
Indicative ·
69 / 100
View asset →
Kidney NeoplasmDormant
BB
Indicative ·
67 / 100
View asset →
renal cell carcinomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →